Studies of bortezomib in patients with relapsed multiple myeloma (MM) suggested that bortezomib may be active even in the presence of adverse prognostic factors. We therefore evaluated 62 patients with relapsed/refractory MM who were treated with single-agent bortezomib, and addressed the question whether or not the negative prognostic impact of unfavorable cytogenetic abnormalities may be overcome by bortezomib. By interphase fluorescence in situ hybridization (FISH), a deletion of chromosome 13q14 [del(13q14)] was present in 33 patients (53%). Overall response rates to bortezomib were similar in patients with and without del(13q14) (45 versus 55%; P ¼ 0.66), and rates of complete remission (CR) near CR were also not different between the two patient populations (18 versus 14%). Three patients had a t(4;14)(p16;q32) in addition to del(13q14), and all of them had a 450% paraprotein reduction. Median duration of response was 12.3 months in patients with del(13q14) compared with 9.3 months in patients with normal 13q-status (P ¼ 0.25), and survival was also not different between the two patient populations. Patients not benefiting from single-agent bortezomib were characterized by the combined presence of a del(13q14) and low serum albumin (median survival 4.6 months). Our results provide evidence for remarkable activity of bortezomib in MM with del(13q14). Patients who do not respond to bortezomib and consecutively have short time to treatment failure and overall survival can be identified by low serum albumin in addition to del(13q14) and should be considered for bortezomib combinations.
Introduction
Multiple myeloma (MM) represents a neoplastic disorder characterized by expansion and accumulation of clonal plasma cells within the bone marrow, a monoclonal immunoglobulin in serum and/or urine, and osteolytic bone lesions. Although treatment strategies of MM have been improved over the past decade, particularly through high-dose chemotherapy followed by autologous stem-cell transplantation, 1,2 MM still remains an incurable hematological malignancy. Until recently, MM patients eventually relapse and become refractory to established treatment options, which emphasizes the urgent need for novel, effective agents in this disease.
Bortezomib (Velcade, formerly PS-341), a reversible inhibitor of the chymotrypsin-like activity of the proteasome, 3 directly inhibits proliferation and induces apoptosis in myeloma cells. In addition, bortezomib acts via interference of myeloma cell interactions with the bone marrow microenvironment, enhances sensitivity to chemotherapy, and reverses resistance to standard therapeutic agents, such as dexamethasone, doxorubicin and melphalan by overcoming nuclear factor (NF)-kappaB activation. [4] [5] [6] The clinical activity of bortezomib was first shown in a phase 2 study in heavily pretreated and mostly chemotherapy refractory MM patients (SUMMIT) 7 and was then confirmed in a large phase 3 study (APEX), which compared bortezomib with high-dose dexamethasone in relapsed MM patients. 8 In these trials, analysis of prognostic factors indicated that bortezomib may be active in patients in whom other therapeutic approaches frequently fail. 7, 9 This was particularly evident in the context of elevated serum b-2-microglobulin (b 2 -M) levels, generally considered as a factor of poor outcome after chemotherapy, [10] [11] [12] and in subsets of patients tested for abnormalities of chromosome 13q (Jagannath et al. Proc ASCO 2005; 23: 560s; abstract). 9 Several groups have confirmed the negative impact of a chromosome 13q-deletion [del(13q14)] on outcome after standard-dose chemotherapy and high-dose therapy with autologous stem-cell transplantation. 11, [13] [14] [15] [16] This negative prognostic information appears to persist even in the setting of allogeneic transplantation 17 underlining the need for effective therapy in such high-risk MM patients.
Therefore, the aim of our investigation was to study the activity of bortezomib in relapsed MM in the context of chromosomal aberrations (in particular del(13q14) and 14q-translocations [t(14q32)]).
Patients and methods

Patient characteristics
The study was performed on a consecutive cohort of 62 patients with relapsed and chemotherapy refractory MM. Diagnosis was made according to the Durie and Salmon Staging System. 18 The median time from initiation of first-line therapy to treatment with bortezomib was 3.1 years (range: 0.3-15.1 years). Pertinent clinical and laboratory features are summarized in Table 1 .
Treatment regimen and evaluation of outcome
Bortezomib was administered at 1.3 mg/m 2 as an intravenous bolus twice weekly for 2 weeks (days 1, 4, 8 and 11) followed by a 10-day rest period (days [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Patients were considered to be evaluable for outcome after completion of at least two cycles of bortezomib. Response to therapy was defined according to the recently established criteria of the European Group for Blood and Marrow Transplantation. 19 Similar to previous reports, a response category termed near complete response (nearCR) was included; nearCR was defined as stable bone disease and a normalization of serum parameters including calcium and electrophoresis, but persistent detection of the paraprotein by immunofixation. 9 Duration of response (DoR) was assessed only in patients who responded to bortezomib; DoR was defined as the time from date of first evidence of achievement of at least a minor response (MR) until date of disease progression or death from any cause. Time to treatment failure (TTF) was defined as the interval between initiation of therapy with bortezomib until documentation of disease progression or death from any cause. Overall survival (OS) was calculated between the time of initiation of therapy with bortezomib and death from any cause. Data on patients who were alive at the time of analysis were censored in the survival analysis on the last date of follow-up known to be alive.
Interphase fluorescence in situ hybridization studies
For fluorescence in situ hybridization (FISH) analysis, the bone marrow samples were obtained and prepared as described previously. 14, 20, 21 FISH analyses were performed as doublecolor hybridizations and combined with detection of cytoplasmic immunoglobulin light chains (cIg-FISH) to identify the clonotypic plasma cells.
Probes used in this study included a DNA probe specific for the retinomablastoma gene-1 locus at 13q14 to detect a chromosome 13q-deletion [del(13q)], a probe set specific for the C H /V H regions of the immunoglobulin heavy-chain gene locus at 14q32 to detect any 14q-translocation [t(14q32)], and specific fusion probes to identify the translocations t(4;14)(p16.3;q32) and t(11;14)(q13;q32) (all probes were purchased from Vysis Inc., Downers Grove, IL, USA).
In every patient, at least 100 cIg-positive plasma cells were scored for each abnormality. We used an immunofluorescence microscope equipped with a triple band-pass filter to simultaneously visualize 4 0 ,6-diamidino-2-phenylindole (DAPI), fluorescein-isothiocyanate (FITC)/Spectrum-green and Spectrumorange (Axioplan-2, Zeiss, Jena, Germany).
Statistical analyses
Differences between groups were compared using the w 2 test, and Kaplan-Meier estimates were used to study survival times. Survival curves were compared by the log-rank test and survival data were analyzed as of September 12, 2006 .
Results
Overall treatment outcome after bortezomib
In this population of 62 patients with heavily pre-treated MM (median number of prior lines of therapy: 3, range: 1-9), the overall response rate of single-agent bortezomib was 52%. A complete remission (CR) or nearCR was observed in 11 patients (18%); 18 patients (29%) achieved a partial response (PR) and three patients (5%) had a MR. Median DoR was 10.0 months, median TTF was 4.8 months and median OS was 15.1 months.
Prior therapy (thalidomide versus no prior thalidomide; high-dose therapy versus standard-dose therapy only) did not influence response rates to bortezomib and survival (data not shown).
Influence of a del(13q14) on outcome after bortezomib
By interphase FISH, a del(13q14) was detected in 33 of 62 patients (53%). Median time from initiation of first-line therapy to start of bortezomib was shorter in patients with a del(13q14) (26 months) compared to patients with normal 13q-status by FISH (51 months; P ¼ 0.02). As depicted in Figure 1a , responses to bortezomib were observed in 15 of 33 patients (45%) with a del(13q14) and in 16 of 29 patients (55%) with a normal chromosome 13q pattern by FISH (P ¼ 0.66). Duration of response was also similar in patients with and without a del(13q14) (12.3 versus 9.3 months, P ¼ 0.25) (compare Figure 1b) , and OS of patients with bortezomibresponsive MM was independent of the chromosome 13q-status (compare Figure 1c) .
Analysis of the entire patient population revealed a trend towards shorter median TTF (4.6 versus 6.7 months; P ¼ 0.95) as well as shorter median OS (9.9 months versus median not yet reached; P ¼ 0.057) in patients with del(13q14) compared to the 13q-normal patients. These differences were due to a rapidly progressive clinical course of patients with a del(13q14) who did not achieve a response to bortezomib.
14q32-translocations
Evidence for any 14q32-translocation as detected by FISH was obtained in 28 of 59 patients (47.5%). The presence or absence of any t(14q32) did not influence the outcome after bortezomib (response rate: 50 versus 45%, P ¼ 0.9; median TTF: 4.9 versus 4.5 months, P ¼ 0.29; median OS: 16.7 versus 14.6 months; P ¼ 0.77).
Patient subgroups with t(4;14)(p16;q32) and t(11;14)(q13;q32) were analyzed separately (compare Figure 2) . Whereas all three patients with a t (4;14) , which was present in addition to a del(13q14), experienced a PR to bortezomib (450% paraprotein reduction in all cases), only two of eight patients with a t(11;14) had a response corresponding to a PR. Time to treatment failure of patients with a t(4;14) was 11, 21 and 40 þ weeks, respectively, and thus appeared to be in the range observed with patients carrying a t(11;14) (Figure 2b ). 
Standard laboratory parameters
We analyzed the importance of b 2 -M and serum albumin, which were recently recognized as dominant prognostic laboratory parameters in the International Staging System (ISS). 12 Similar response rates to bortezomib were observed for patients with high (43.5 mg/l) and low (p3.5 mg/l) b 2 -M (51 versus 49%, P ¼ 0.94). Also, median TTF (5.0 versus 4.4 months; P ¼ 0.58) and median OS (not reached in both subgroups, P ¼ 0.72) were not different between patients with high and low b 2 -M.
With respect to serum albumin, a trend towards poorer response rates was observed for patients with low serum levels (o3.5 g/dl): 32 versus 68% in patients with albumin X3.5 g/dl (P ¼ 0.17). As illustrated in Figure 3 , low serum albumin was also associated with a trend towards short median OS (7.7 versus 22.6 months, P ¼ 0.087).
Using serum albumin and the chromosome 13q-status by FISH, a risk model was established to estimate the outcome after treatment with bortezomib ( Figure 4 ): patients with del(13q14) and low serum albumin had short OS (median 4.6 months); in contrast, patients with a normal 13q status and serum albumin X3.5 g/dl had favorable OS times (median not yet reached). Patients with either a del(13q14) or low serum albumin had an intermediate prognosis after treatment with bortezomib (median OS, 14.5 months).
Discussion
In this analysis, we demonstrate that response rates as well as duration of response are independent of the chromosome 13q status of relapsed MM patients. Together with the observation of marked responses in patients with a translocation t(4;14), another recognized poor prognostic parameter even with high-dose therapy, 16, [22] [23] [24] [25] these results suggest that bortezomib is an active agent for MM patients with high-risk cytogenetic features. Moreover, high serum levels of b 2 -M, a dominantnegative prognostic indicator in MM patients treated with chemotherapy [10] [11] [12] or thalidomide, 26 were not correlated with adverse outcome after bortezomib in our investigation.
It is important to point out that marked differences regarding responsiveness to bortezomib existed among the patient population with a del(13q14): In contrast to the favorable outcome of bortezomib-responsive patients, patients with a del(13q14) and failure to respond to bortezomib were characterized by rapid disease progression usually within two cycles of bortezomib. As a consequence, shortened TTF and OS were observed, when the entire patient population with a del(13q14) was considered. Therefore, we sought to identify additional parameters to better define patients who derive a benefit from treatment with single-agent bortezomib. Among standard laboratory parameters, low serum albumin turned out to be helpful in identifying patients with poor outcome after treatment with bortezomib, and the combined presence of a del(13q14) and low serum albumin defined a patient subgroup with very short survival after bortezomib.
In two previous trials with bortezomib-monotherapy, 7, 8 baseline demographic and disease parameters were analyzed to determine their value in predicting outcome. Regarding cytogenetics, metaphase analysis was performed in subsets of patients enrolled into the SUMMIT and APEX trials (Jagannath et al. Proc ASCO 2005; 23: 560s; abstract). 9 In the SUMMIT trial, chromosome 13 deletion was demonstrated in 25 of 162 patients (15%), but there was no association with response to bortezomib, time to progression or OS. Likewise, in patients studied in the APEX trial, response rates to bortezomib were similar in patients with and without a chromosome 13q-deletion, again as determined by metaphase analysis. In contrast, patients in the dexamethasone arm of this trial had poor outcome when a chromosome 13 abnormality was present, which is in agreement with previous observations with standard-dose treatment and high-dose therapy. Of note, there are two differences between these studies and our present investigation: first, in contrast to the post hoc analysis of SUMMIT and APEX patient subsets, patients in our investigation represented a consecutive group of relapsed MM patients who were treated with singleagent bortezomib. Second, we performed interphase FISH to detect a del(13q14), which yields higher detection rates than metaphase cytogenetics. 14, 16 Metaphase-defined presence of a chromosome 13 abnormality appears to be an even stronger adverse parameter in MM, probably due to the high proliferative capacity of such cases. 27, 28 Nevertheless, del(13q14) as determined by FISH has remained a negative prognostic factor in many investigations. 11, [14] [15] [16] [17] These findings are further substantiated by our current investigation showing shorter interval from the start of initial treatment to start of bortezomib therapy in patients with del(13q14) and by the very short survival of those patients with del(13q14), who did not respond to bortezomib.
The new ISS for MM identified two laboratory parameters that were most informative in the pre-treatment evaluation of patients with MM: b 2 -M reflecting tumor burden and serum albumin, which is associated with myeloma cell growth kinetics. 12 Results obtained in the SUMMIT trial suggested that clinical outcome with bortezomib was independent of b 2 -M. 9 Low serum albumin, however, was associated with shorter DoR and OS. 9 Although obtained in a smaller group of relapsed MM patients, our results are in agreement with these previous observations and thus confirm that prognostic factors with bortezomib therapy are quite different from those described with chemotherapy and also with thalidomide.
In conclusion, bortezomib has emerged as the only agent with remarkable activity in MM patients with adverse cytogenetic features. Our analysis also shows that favorable survival times are generally limited to those patients without additional adverse prognostic factors such as low serum albumin or del(13q14). Future studies should explore the value of earlier initiation of bortezomib and of bortezomib combinations in patients with cytogenetic risk factors. Furthermore, studies should be continued to further evaluate the role of gene expression profiling 29 for the identification of high-risk patients likely to benefit from bortezomib and other novel drugs in MM therapy. 
